{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-048042","form_type":"8-K","ticker":"ABCL","cik":"0001703057","company_name":"AbCellera Biologics Inc.","filed_at":"2021-09-15T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.281115+00:00","generated_at":"2026-06-29T03:34:36.320653+00:00","sec_items":["8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"AbCellera acquires TetraGenetics for $12.5M upfront to boost antibody discovery","bullets":["Upfront cash consideration of $12.5M; additional technical, development, and commercial milestones possible.","TetraGenetics specializes in recombinant ion channels, GPCRs, and other transmembrane proteins.","Acquisition integrates TetraGenetics' protein expression platform into AbCellera's antibody discovery stack.","Deal aims to unlock antibody therapies against difficult-to-drug transmembrane targets."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-048042","json":"https://secwatch.observer/filing/0001564590-21-048042.json","markdown":"https://secwatch.observer/filing/0001564590-21-048042.md","text":"https://secwatch.observer/filing/0001564590-21-048042.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703057/000156459021048042/0001564590-21-048042-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703057/000156459021048042/abcl-8k_20210913.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T03:34:36.320653+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}